SOURCE: Healtheuniverse, Inc.

July 31, 2006 09:30 ET

Healtheuniverse Announces Strategic Expansion Plans in Singapore

Asian Corporate Headquarters and Research Development Laboratory to Advance Stem Cell Based Applications as Company Moves to Clinical Trials

COVINA, CA -- (MARKET WIRE) -- July 31, 2006 -- Healtheuniverse Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products announced today that it is completing its infrastructure development in Singapore with operations expected to begin in September 2006. Corporate headquarters for Asian operations and the research development laboratories for its proprietary stem cell based applications will be housed in Biopolis, Singapore. The wholly owned subsidiary will collaborate with other research and development facilities in Asia in preparation for clinical trials. The planned expansion is a key step in the Company's move to be the first to commercialize the use of stem cell based applications and regenerative medicine in the $15 billion worldwide plastic, reconstructive and cosmetic surgery market.

"Our facilities in Singapore will cut R&D costs significantly while accelerating our product development and commercialization timeline," stated Dr.Vipul Dev, M.D. Chief Executive Officer of Healtheuniverse, Inc. "We will also benefit greatly from the Singapore governments commitment to doing its utmost to minimize any obstacles and hindrances to our biomedical research efforts. The local talent base of scientists in Singapore is exceptional and we have forged collaborative relationships that will be essential to making commercially viable stem cell based products a reality."

About Biopolis Singapore

Biopolis is a biomedical research hub where researchers from the public and private sectors are co-located. Situated in the south-western part of Singapore, the Biopolis is near both the National University of Singapore and the National University Hospital. The five biomedical research institutes of A*STAR, BioInformatics Institute (BII), the Bioprocessing Technology Institute (BTI), the Genome Institute of Singapore (GIS), the Institute of Molecular and Cell Biology (IMCB) and the Institute of Bioengineering & Nanotechnology (IBN) are co-located at the Biopolis.

About HEALTHeUNIVERSE Inc.

HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    800-719-7424
    Email Contact